Eli Lilly (LLY)
NYSE Market Closed
Eli Lilly & Co. is a global pharmaceutical company focused on discovering, developing, manufacturing, and commercialising prescription medicines. The company has a long history in diabetes care and has expanded into several high-value therapeutic areas, including obesity, oncology, immunology, neuroscience, and cardiometabolic disease. Lilly sells medicines through healthcare systems, pharmacies, hospitals, and specialist channels in the United States and international markets.
A central part of Lilly’s current profile is its cardiometabolic portfolio. Mounjaro, used for type 2 diabetes, and Zepbound, used for chronic weight management, are based on tirzepatide and have become major growth drivers as demand for GLP-1 and related incretin therapies increases. Lilly also markets established diabetes products such as Trulicity, Jardiance, Humalog, and Humulin, giving it broad exposure across modern and legacy diabetes treatment.
Beyond metabolic disease, Lilly has important positions in cancer and immunology. Verzenio is used in certain breast cancer settings, while Jaypirca targets specific blood cancers. Taltz and Olumiant are part of the company’s immunology franchise, addressing inflammatory and autoimmune conditions. In neuroscience, Lilly is active in areas such as Alzheimer’s disease and migraine, supported by a research pipeline that aims to produce differentiated therapies for complex neurological disorders.
The company’s investment case is closely tied to product innovation, clinical trial execution, regulatory approvals, manufacturing capacity, and pricing dynamics. Lilly competes with other large drugmakers but stands out for the scale of its obesity and diabetes opportunity, its strong research base, and its ability to turn specialised medicines into global commercial franchises.
Last updated
- Market Cap
- 948.95B
- P/E
- 37.54
- P/FCF
- 80.26
- P/S
- 13.13
- Enterprise Value
- 987.03B
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- LILLY CORPORATE CTR, INDIANAPOLIS, IN, 46285
Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma
Therini Bio Doses First Patients in Phase 1b Trial of Novel Anti-Inflammatory Therapy, THN391, for Diabetic Macular Edema
From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight
Sitryx to Participate in Upcoming Investor Conferences
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight
Global AI in Life Sciences Market Gearing Up for Outstanding Expansion at a CAGR of ~20% by 2034 | DelveInsight
Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight
First-in-Class Oral PKM2 Modulator SYX-5219 Phase 1a Trial Data to be Presented at SID 2026
Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
Narrow Tech Leadership Continues as Oil and Rates Fall
$9 Trillion Is Pouring Into American Manufacturing — And It’s Just Getting Started
Lilly’s Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026
Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started
Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape
Mag 7 Earnings Bonanza, Fed Await Stocks at Record Highs: What to Expect
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 948.95B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 987.03B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 37.54
- P/B
P/B ratio compares a company's share price to its book value per share.
- 30.42
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 13.13
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 27.25
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 13.66
- EPS
- 28.35
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0.59%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 80.26
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 46.33
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 11.82B
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 81.02%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 21.68%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 1.39
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.5
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.1
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.14
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 3.41M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 1,064.15
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 19.8B | 19.29B | 17.6B | 15.56B | 12.73B |
| Gross profit | 16.22B | 15.92B | 14.59B | 13.11B | 10.5B |
| Operating income | 8.92B | 8.37B | 7.37B | 6.87B | 3.7B |
| EBITDA | 10.29B | 9.57B | 8.86B | 7.5B | 5.77B |
| Net income | 7.4B | 6.64B | 5.58B | 5.66B | 2.76B |
| Basic EPS | 8.27 | 7.4 | 6.22 | 6.3 | 3.07 |
| Diluted EPS | 8.26 | 7.39 | 6.21 | 6.29 | 3.06 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 116.58B | 112.48B | 114.94B | 100.92B | 89.39B |
| Total liabilities | 85.38B | 85.94B | 91.08B | 82.57B | 73.54B |
| Total equity | 31.2B | 26.54B | 23.85B | 18.35B | 15.85B |
| Cash & equivalents | 5.28B | 7.27B | 9.79B | 3.38B | 3.09B |
| Current assets | 54.84B | 55.63B | 62.07B | 49.85B | 41.26B |
| Current liabilities | 36.63B | 35.23B | 40.14B | 39.02B | 30.07B |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 5.33B | 3.22B | 8.84B | 3.09B | 1.67B |
| Investing cash flow | -3.92B | -2.8B | -2.98B | -1.83B | -3.35B |
| Financing cash flow | -3.47B | -2.88B | 531M | -1.24B | 1.38B |
| Change in cash | -1.99B | -2.52B | 6.42B | 282.6M | -175M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 8-K — ELI LILLY & Co | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing | |
| form 4 | Form 4 — Sulzberger Gabrielle | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| edgar index | SD — ELI LILLY & Co | View Filing | |
| edgar index | 424B2 — ELI LILLY & Co | View Filing | |
| edgar index | 8-K — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 424B2 — ELI LILLY & Co | View Filing | |
| edgar index | FWP — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — LILLY ENDOWMENT INC | View Filing | |
| form 4 | Form 4 — LILLY ENDOWMENT INC | View Filing | |
| edgar index | SCHEDULE 13G — ELI LILLY & Co | View Filing | |
| edgar index | PX14A6G — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | SCHEDULE 13G/A — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing | |
| form 4 | Form 4 — Sulzberger Gabrielle | View Filing | |
| edgar index | SCHEDULE 13G/A — ELI LILLY & Co | View Filing | |
| edgar index | DEF 14A — ELI LILLY & Co | View Filing | |
| edgar index | DEFA14A — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing | |
| form 4 | Form 4 — Sulzberger Gabrielle | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| edgar index | PRE 14A — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Dozier Eric | View Filing | |
| form 4 | Form 4 — Dozier Eric | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing | |
| form 4 | Form 4 — Sulzberger Gabrielle | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Zakrowski Donald A | View Filing | |
| form 4 | Form 4 — Zakrowski Donald A | View Filing | |
| form 4 | Form 4 — Zakrowski Donald A | View Filing | |
| form 4 | Form 4 — Zakrowski Donald A | View Filing | |
| form 4 | Form 4 — Montarce Lucas | View Filing | |
| form 4 | Form 4 — Montarce Lucas | View Filing | |
| form 4 | Form 4 — Montarce Lucas | View Filing | |
| form 4 | Form 4 — Custer Kenneth L. | View Filing | |
| form 4 | Form 4 — Custer Kenneth L. | View Filing | |
| form 4 | Form 4 — Custer Kenneth L. | View Filing |